Dr. Reddy's Labs

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Doctor Reddy's (RDY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Doctor Reddy's (RDY) Loses -6.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Interactive Brokers

Vistra Energy

Low-beta stocks can provide many beneficial advantages for investors, including a more defensive nature and overall portfolio balance.

Navigate Volatility With These 3 Low-Beta Stocks

Caterpillar

Owens Corning

In the ever-evolving financial markets, savvy investors are always on the lookout for golden opportunities that offer great value. While the headlines often spotlight stocks that are soaring to new heights, some of the best investment prospects lie in stocks trading below their historical valuations.

Discount Alert: 3 Top Ranked Stocks Trading Below Historical Valuations

Doctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes.

Here is Why Growth Investors Should Buy Doctor Reddy's (RDY) Now

FedEx

KB Home

Walmart

Caterpillar (CAT), KB Home (KBH), Walmart (WMT), Dr. Reddy's (RDY) and FedEx (FDX) could be solid choices amid the current market volatility.

5 Dividend Growth Stocks for Steady Returns in Uncertain Times

Arch Capital

Allison Transmission Hlds

Low-beta stocks can provide many beneficial advantages for investors, including a more defensive nature and overall portfolio balance. And for those seeking this approach, these three stocks are great considerations.

These 3 Low-Beta Stocks Sport High Growth

Looking for a Growth Stock? 3 Reasons Why Doctor Reddy's (RDY) is a Solid Choice

Applied Materials

Toll Brothers

Caterpillar (CAT), Applied Materials (AMAT), Toll Brothers (TOL), Walmart (WMT) and Dr. Reddy's (RDY) could be solid choices for investors amid market weakness.

5 Dividend Growth Stocks to Buy in a Weak Market

Granite Ridge Resources Inc

J & J Snack Foods

Trip.com

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), Dr. Reddy's (RDY), J&J Snack (JJSF) and Granite Ridge (GRNT) are poised to gain.

Buy These 4 Low-Beta Stocks to Sail Through the Choppy Market

Dr. Reddy's Laboratories stock remains an attractive long-term investment. The company's Q1 FY'24 earnings showed strong growth in total revenues and gross margins, driven by sales expansion in its generic business. RDY's growth is supported by manageable working capital and cash flows, allowing for sustainable expansion.

Dr. Reddy's: Growth Supported By New Labels, Profitability

Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looking to strengthen its biosimilars portfolio.

Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio

DMC Global

Encompass Health

Huron Consulting Group

Hawkins

HURN, EHC, RDY, BOOM and HWKN are five stocks with explosive relative price strength.

5 Growth Opportunities Thriving on Relative Price Strength

Fluor

Gigacloud Tech

Surmodics

Here are four top-ranked liquid stocks, Dr. Reddy's (RDY), Surmodics (SRDX), Fluor Corporation (FLR) and GigaCloud Technology (GCT), which investors can add to their portfolio for solid gains.

Add These 4 Top-Performing Liquid Stocks for Strong Returns

Doctor Reddy's (RDY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Dr. Reddy's Laboratories Ltd (RDY) Hits Fresh High: Is There Still Room to Run?

Progress Software

Caterpillar (CAT), Walmart (WMT), KB Home (KBH), Progress Software (PRGS) and Dr. Reddy's (RDY) could be solid choices for your portfolio.

5 Dividend Growth Stocks for Safe and Stable Returns

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories announces its launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.

Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.

MINISO Group Holding

Sterling Check Corp

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), Dr. Reddy's (RDY), Sterling Check (STER) and MINISO Group (MNSO) are poised to gain.

Buy These 4 Low-Beta Stocks to Counter the Choppy Market

Dr. Reddy's (RDY) reports better-than-expected fiscal first-quarter 2024 results.

Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates

Dr Reddy's Laboratories Ltd (NYSE:RDY ) Q1 2024 Earnings Conference Call July 26, 2023 10:00 AM ET Company Participants Richa Periwal - IR Erez Israeli - CEO Parag Agarwal - CFO Conference Call Participants Kunal Dhamesha - Macquarie Research Damayanti Kerai - HSBC Surya Patra – Phillip Capital India Private Limited Neha Manpuria - Bank of America Merrill Lynch Cyndrella Carvalho - JM Financial Tushar Manudhane - Motilal Oswal Financial Services Shyam Srinivasan - Goldman Sachs Sayon Mukherjee - Nomura Binopati Parampil - Ilara Capital Ankush Mahajan - Axis Securities Operator Ladies and gentlemen, good day and welcome to the Dr. Reddy's Q1 FY '24 Earnings Call. [Operator Instructions].

Dr Reddy's Laboratories Ltd (RDY) Q1 2024 Earnings Call Transcript

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2023.

Dr. Reddy's Q1 FY24 Financial Results

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #BiologicsLicenseApplication--Dr. Reddy's proposed rituximab biosimilar application accepted for review by USFDA, EMA and MHRA.

Dr. Reddy's Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA

Dr. Reddy's Laboratories Ltd. (RDY) remains an attractive investment due to its strong Q4 and FY'23 numbers, exposure to the Indian generics market, and consistent new product launches. RDY is well-positioned in the high-growth generics market, along with other favorable business economics. Findings suggest RDY stock could be a buy with a target price of $60/share.

Dr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate Buy

Dr. Reddy's (RDY) announces meeting primary and secondary endpoints in the phase I study of its proposed tocilizumab biosimilar for the treatment of rheumatoid arthritis in adults.

Dr. Reddy's (RDY) Meets Goals in Actemra Biosimilar Study

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRL_TC--Dr. Reddy's announced that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study.

Dr. Reddy's Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab

Inmode Ltd

Ternium

With the market facing myriad pressure points – predominantly stubbornly high inflation along with general anxieties about an incoming recession – the bright side is that investors have options regarding the best undervalued value stocks for June. Still, you don't want to just chase deflated entities just because they're down.

The 3 Most Undervalued Value Stocks to Buy in June 2023

News for Dr. Reddy's Labs Stock (RDY)